Composition for prophylaxis, Treatment and reduction of exacerbations associated with Lung Disease and use of an effective amount of a PDE4 inhibitor and an effective amount of an H1 Receptor Antagonist for its Manufacture.

摘要

Composition for prophylaxis, Treatment and reduction of exacerbations associated with lung disease which comprises an effective amount of a PDE4 Inhibitor, an effective amount of an H1 Receptor Antagonist, and a pharmaceutically acceptable excipient.The PDE4 inhibitor can be cis - [cyano - 4 - (3 - (4-methoxyphenyl ciclohexan cyclopentyloxy) - 1] - carboxylate, roflumilast or N - (3,5 - dicloropirid - 4-yl) - 2 - [1 - (4-fluorobenzyl) - - - - 3 - 5 hidroxiindol il] - 2 - oxoacetamida) and H1 Receptor antagonist is astemizole, levocabastine HCl, Loratadine or composed Or similar descarboetoxilado, terfenadine, or Fexofenadine hydrochloride.The composition can be in the form of an oral tablet, a dry powder Inhaler for use in a dry powder, or an aqueous preparation for nasal Administration. Use of an effective amount of a PDE4 inhibitor and an effective amount of an H1 Receptor Antagonist for the manufacture of said Pharmaceutical composition.